Related Experiment Video
Updated: Aug 8, 2026

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Clinical importance of microbleeds in patients receiving IV thrombolysis
W Kakuda1, V N Thijs, M G Lansberg
1Stanford Stroke Center, Stanford University Medical Center, Palo Alto, CA, USA. wkakuda@stanford.edu
Background:
Cerebral microbleeds (MBs) detected on gradient echo (GRE) imaging may be a risk factor for hemorrhagic complications in patients with stroke treated with IV tissue plasminogen activator (tPA).
Methods:
The authors prospectively evaluated patients with acute ischemic stroke treated with IV tPA between 3 and 6 hours of symptom onset. MRI scans, including GRE imaging, were performed prior to tPA treatment, 3 to 6 hours after treatment and at day 30. The authors compared the frequency of hemorrhagic complications after thrombolysis in patients with and without MBs on their baseline GRE imaging.
Results:
Seventy consecutive patients (mean age, 71 +/- 29 years; 31 men, 39 women) were included. MBs were identified in 11 patients (15.7%) on baseline GRE imaging. There was no significant difference in the frequency of either symptomatic or asymptomatic hemorrhagic complications after thrombolysis between patients with and without MBs at baseline. None of the 11 patients with MBs (0%) at baseline had a symptomatic intracerebral hemorrhage compared with 7 of 59 patients who did not have baseline MBs (11.9%). In addition, no patients with baseline MBs had asymptomatic hemorrhagic transformation observed at the site of any pre-treatment MB.
Conclusions:
The presence of cerebral microbleeds on gradient echo imaging does not appear to substantially increase the risk of either symptomatic or asymptomatic brain hemorrhage following IV tissue plasminogen activator administered between 3 and 6 hours after stroke onset.
Insights
Cerebral microbleeds (MBs) on gradient echo imaging do not significantly increase the risk of brain hemorrhage in stroke patients receiving IV tissue plasminogen activator (tPA) within 3 to 6 hours of symptom onset.
Area of Science:
- Neurology
- Radiology
- Cardiovascular Research
Background:
- Cerebral microbleeds (MBs) detected by gradient echo (GRE) imaging are a potential risk factor for hemorrhagic complications.
- Intravenous tissue plasminogen activator (IV tPA) is a common treatment for acute ischemic stroke.
Purpose of the Study:
- To investigate the association between baseline cerebral microbleeds (MBs) and hemorrhagic complications after IV tPA treatment in acute ischemic stroke patients.
- To determine if pre-existing MBs increase the risk of symptomatic or asymptomatic hemorrhage following thrombolysis.
Main Methods:
- Prospective evaluation of acute ischemic stroke patients treated with IV tPA within 3-6 hours of symptom onset.
- MRI scans including GRE imaging performed before, during, and after IV tPA treatment.
- Comparison of hemorrhagic complication rates in patients with and without baseline MBs.
Main Results:
- MBs were identified in 15.7% of patients on baseline GRE imaging.
- No significant difference in symptomatic or asymptomatic hemorrhagic complications was observed between patients with and without baseline MBs.
- Patients with baseline MBs had a 0% rate of symptomatic intracerebral hemorrhage compared to 11.9% in those without MBs.
Conclusions:
- The presence of cerebral microbleeds on GRE imaging does not substantially elevate the risk of brain hemorrhage after IV tPA administration.
- This finding suggests that IV tPA can be safely administered in stroke patients with MBs detected on baseline GRE imaging within the specified time window.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology

